相关实验视频

Updated: Sep 18, 2025

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

多巴胺D3受体的偏向信号激活剂不同调节可卡因对多巴胺载体功能的影响

Sophie R Cohen¹, Wei Xu², Nastaran F Aziz²

¹Dept. of Neurobiology & Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, United States.

ACS chemical neuroscience

|June 26, 2025

概括

新型多巴胺D3受体 (D3R) 激动剂显示出治疗可卡因使用障碍的潜力. 一种偏向G蛋白D3R激动剂,SK609,减少了可卡因的使用.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
成药物药物药物药物

背景情况:

可卡因使用障碍 (CUD) 是一个重要的公共卫生问题,缺乏有效的FDA批准的治疗方法.
可卡因的主要机制涉及阻断多巴胺载体 (DAT),破坏多巴胺信号传递.
多巴胺D3受体 (D3R) 参与调节DAT功能,并且在中边路径中高度表达,这是奖励和成的关键区域.

研究的目的:

研究一种新型G蛋白偏向D3R激活剂 (SK609) 和一种无偏向D3R激活剂 (pramipexole) 对DAT功能和寻找可卡因的行为的影响.
为了确定有偏见的D3R激动能否减轻可卡因的影响,与无偏见的激动不同.

主要方法:

利用体外和体外研究来评估DAT酸化和多巴胺吸收抑制.
在SK609和pramipexole的使用后,评估了大鼠寻找可卡因的行为.
对比了G蛋白偏差D3R激活剂 (SK609) 与无偏差D3R激活剂 (普拉米醇) 的作用.

主要成果:

SK609显著降低了可卡因暴露后的DAT酸化,并抑制了可卡因对多巴胺传播的影响.
相反,pramipexole增加了可卡因诱导的DAT酸化,增加了多巴胺水平,并在老鼠中增强了寻找可卡因的行为.
在可卡因的神经生物学和行为影响上,有偏见与无偏见的D3R激动因子对可卡因的影响有所区别.

结论:

公正的D3R激活似乎会增强可卡因的影响,包括增加多巴胺传输和寻求行为.
像SK609这样的G蛋白偏向的D3R激应剂可能通过抵消可卡因的影响来提供治疗策略.
选择性地准D3R信号通路可能是开发可卡因使用障碍新型治疗方法的有希望的方法.

关键词:

G-蛋白偏向性激素抗体在 SK609 的位置上.这是一种β-arrestin2的组合.在寻找可卡因的过程中.可卡因自我管理多巴胺D3受体的受体多巴胺运输体是多巴胺的运输体.快速扫描循环电压计快速扫描酸化的方法是光化.在这种情况下,pramipexole会被认为是pramipexole.

更多相关视频

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Presynaptic Dopamine Dynamics in Striatal Brain Slices with Fast-scan Cyclic Voltammetry

Presynaptic Dopamine Dynamics in Striatal Brain Slices with Fast-scan Cyclic Voltammetry

Published on: January 12, 2012

相关概念视频

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...